Hospital
HMH Hospitals Corporation
HMH Hospitals Corporation was paid $72.16M by Medicaid between Jul 2021 and Dec 2024, across 376 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoHMH HOSPITALS CORPORATION
EDISON, NJ 08820
EDISON, NJ 08820
33aNPI1144894577assigned 05/19/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$72.16M
24GClaims1,161,793
24DCodes billed376
24AFirst – last monthJul 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#24 of 93
Median peer was paid$30.60M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 3,955 | $87K | |
| 2022 | 388,899 | $23.69M | |
| 2023 | 428,496 | $25.81M | |
| 2024incomplete | 340,443 | $22.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 40,489 | 37,265 | $11.64M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 30,754 | 27,767 | $10.24M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 11% | 25,197 | 20,101 | $7.81M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 5.5% | 13,825 | 12,299 | $3.97M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 4.7% | 4,975 | 4,485 | $3.41M |
| G0378 | Hospital observation service, per hour | 3.6% | 6,412 | 5,162 | $2.60M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.5% | 5,799 | 5,318 | $2.55M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.0% | 5,912 | 5,332 | $2.17M |
| A0434 | Specialty care transport (sct) | 2.2% | 3,762 | 3,115 | $1.61M |
| 93017 | 2.1% | 6,493 | 5,704 | $1.54M | |
| 93458 | 2.1% | 1,256 | 1,059 | $1.49M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 10,693 | 10,045 | $1.43M |
364 more codes
| A0425 | Ground mileage, per statute mile | 1.6% | 52,331 | $1.12M |
| 29581 | 1.4% | 2,688 | $1.02M | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.3% | 1,415 | $933K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 4,971 | $813K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.0% | 1,917 | $734K |
| OP370 | <1% | 5,090 | $698K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,716 | $604K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 8,642 | $582K |
| OP710 | <1% | 3,871 | $442K | |
| 93880 | <1% | 1,756 | $439K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 17,549 | $436K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,748 | $386K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,086 | $373K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 456 | $364K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,515 | $351K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,516 | $348K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 382 | $338K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 5,828 | $336K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,408 | $327K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,992 | $291K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 9,447 | $286K |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 767 | $280K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,882 | $278K |
| OP272 | <1% | 9,366 | $278K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,252 | $270K |
| 80053 | Comprehensive metabolic panel | <1% | 43,253 | $235K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 169 | $226K |
| 64483 | <1% | 310 | $225K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,886 | $221K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,846 | $217K |
| 93970 | <1% | 1,166 | $217K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 622 | $201K |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 129 | $197K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 394 | $191K |
| 95708 | <1% | 295 | $191K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,899 | $186K |
| 29580 | <1% | 3,397 | $182K | |
| 76641 | <1% | 1,054 | $165K | |
| 70496 | <1% | 1,480 | $160K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,639 | $158K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,287 | $154K |
| 72141 | <1% | 436 | $150K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,563 | $141K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,432 | $140K |
| 76801 | <1% | 1,478 | $135K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,685 | $126K |
| 70498 | <1% | 1,344 | $126K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,428 | $125K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,928 | $121K |
| 77066 | Tomosynthesis, mammo | <1% | 874 | $114K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 103 | $114K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 969 | $109K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 546 | $105K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,041 | $103K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,389 | $101K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 133 | $101K |
| 95700 | <1% | 377 | $99K | |
| 93971 | <1% | 832 | $94K | |
| 76642 | <1% | 797 | $94K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,574 | $92K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 808 | $92K |
| 71250 | <1% | 813 | $92K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,526 | $91K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,270 | $89K |
| OP250 | <1% | 77,687 | $86K | |
| 77080 | <1% | 793 | $82K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,155 | $82K |
| 70544 | <1% | 324 | $77K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 343 | $73K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,021 | $73K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,843 | $72K |
| 72110 | <1% | 1,323 | $71K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,882 | $69K |
| 77065 | Tomosynthesis, mammo | <1% | 986 | $68K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,161 | $66K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 431 | $63K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 993 | $55K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 8,213 | $55K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,318 | $55K |
| 73030 | <1% | 1,659 | $54K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,156 | $50K |
| 76536 | <1% | 393 | $49K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,936 | $49K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,399 | $47K |
| 75574 | <1% | 140 | $45K | |
| 76770 | <1% | 608 | $44K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 694 | $43K |
| 84484 | <1% | 16,772 | $42K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 381 | $41K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,392 | $40K |
| 85730 | <1% | 13,086 | $39K | |
| 80061 | Lipid panel | <1% | 5,460 | $38K |
| 93925 | <1% | 151 | $38K | |
| 73564 | <1% | 1,413 | $38K | |
| 85027 | <1% | 11,218 | $37K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,920 | $37K |
| 85610 | <1% | 14,306 | $36K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 51,594 | $36K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 206 | $35K |
| 86900 | <1% | 5,411 | $34K | |
| 73630 | <1% | 1,794 | $34K | |
| 76706 | <1% | 651 | $34K | |
| 81455 | <1% | 295 | $33K | |
| 96367 | <1% | 685 | $33K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 55 | $32K |
| 97602 | <1% | 628 | $32K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 5,593 | $32K |
| OP258 | <1% | 30,663 | $31K | |
| 73130 | <1% | 1,438 | $31K | |
| 76937 | <1% | 1,526 | $31K | |
| C1769 | Guide wire | <1% | 1,639 | $30K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,977 | $29K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,873 | $29K |
| 70486 | <1% | 594 | $29K | |
| OP270 | <1% | 4,977 | $26K | |
| 83880 | <1% | 5,325 | $26K | |
| 74019 | <1% | 1,948 | $23K | |
| 96376 | <1% | 1,753 | $23K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 375 | $21K |
| 86850 | <1% | 5,597 | $21K | |
| 73610 | <1% | 1,773 | $21K | |
| 81025 | <1% | 16,096 | $21K | |
| 47562 | <1% | 12 | $21K | |
| 74018 | <1% | 1,817 | $19K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,846 | $19K |
| 87070 | <1% | 9,520 | $19K | |
| 92083 | <1% | 330 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,671 | $18K |
| 83735 | <1% | 8,837 | $18K | |
| 73562 | <1% | 538 | $17K | |
| 72052 | <1% | 454 | $17K | |
| 81001 | <1% | 16,608 | $17K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 643 | $16K |
| 82962 | <1% | 10,572 | $16K | |
| 76820 | <1% | 197 | $16K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,874 | $16K |
| 73502 | <1% | 906 | $16K | |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 1,881 | $16K |
| 70491 | <1% | 97 | $15K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,350 | $15K |
| 83605 | <1% | 5,855 | $15K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 334 | $15K |
| 86901 | <1% | 5,466 | $15K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 114 | $14K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,497 | $14K |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 2,426 | $14K |
| 72131 | <1% | 233 | $14K | |
| 87040 | <1% | 1,554 | $13K | |
| 19083 | <1% | 13 | $12K | |
| 36430 | <1% | 282 | $12K | |
| 76813 | <1% | 99 | $12K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 359 | $12K |
| 83690 | <1% | 9,119 | $12K | |
| 73110 | <1% | 810 | $12K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,765 | $11K |
| 95811 | <1% | 12 | $11K | |
| 93922 | <1% | 65 | $11K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,969 | $10K |
| 97162 | <1% | 499 | $10K | |
| 82607 | <1% | 1,653 | $10K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 198 | $10K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 224 | $10K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 570 | $10K |
| 84145 | <1% | 2,605 | $10K | |
| 88341 | <1% | 78 | $10K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,515 | $9K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,304 | $9K |
| 84702 | <1% | 2,976 | $9K | |
| 73080 | <1% | 535 | $9K | |
| 90715 | <1% | 1,200 | $9K | |
| 88304 | <1% | 535 | $9K | |
| 86803 | <1% | 717 | $9K | |
| 59025 | Fetal non-stress test | <1% | 111 | $9K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 367 | $9K |
| J3490 | Unclassified drugs | <1% | 4,664 | $9K |
| 92133 | <1% | 323 | $9K | |
| 82077 | <1% | 2,820 | $8K | |
| 97161 | <1% | 415 | $8K | |
| 94375 | <1% | 98 | $8K | |
| 81003 | <1% | 8,030 | $8K | |
| 12001 | <1% | 477 | $8K | |
| 95816 | <1% | 59 | $7K | |
| 73590 | <1% | 646 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,118 | $7K |
| 93976 | <1% | 91 | $7K | |
| 87186 | <1% | 2,068 | $7K | |
| 84153 | <1% | 405 | $7K | |
| 84439 | <1% | 1,524 | $7K | |
| 86140 | <1% | 5,861 | $7K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,262 | $6K |
| 12011 | <1% | 400 | $6K | |
| 72100 | <1% | 408 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,770 | $6K |
| 87340 | <1% | 781 | $6K | |
| 88312 | <1% | 380 | $6K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 219 | $6K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 18 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,095 | $6K |
| 73090 | <1% | 490 | $6K | |
| 94760 | <1% | 382 | $6K | |
| 87480 | <1% | 297 | $6K | |
| 70547 | <1% | 27 | $6K | |
| 87660 | <1% | 297 | $6K | |
| 72197 | <1% | 12 | $6K | |
| 80047 | <1% | 4,153 | $6K | |
| 82728 | <1% | 961 | $5K | |
| 73560 | <1% | 196 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,812 | $5K |
| 80143 | <1% | 1,891 | $5K | |
| 80179 | <1% | 1,865 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,393 | $5K |
| 71271 | <1% | 26 | $5K | |
| 86703 | <1% | 594 | $5K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,742 | $5K |
| 73140 | <1% | 520 | $5K | |
| 95886 | <1% | 58 | $5K | |
| 84100 | <1% | 3,326 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 170 | $4K |
| 29515 | <1% | 160 | $4K | |
| 76870 | <1% | 110 | $4K | |
| 84480 | <1% | 800 | $4K | |
| 88360 | <1% | 97 | $4K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 16 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,687 | $4K |
| 82746 | <1% | 737 | $4K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 267 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $3K |
| C1753 | Catheter, intravascular ultrasound | <1% | 15 | $3K |
| 88342 | <1% | 105 | $3K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 14 | $3K |
| 94729 | <1% | 82 | $3K | |
| 87807 | <1% | 2,822 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,769 | $3K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,026 | $3K |
| 97803 | <1% | 31 | $3K | |
| 15853 | <1% | 77 | $3K | |
| 83550 | <1% | 941 | $3K | |
| 94200 | <1% | 84 | $3K | |
| 96415 | <1% | 18 | $3K | |
| 85379 | <1% | 2,272 | $3K | |
| 95800 | <1% | 14 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 89 | $3K |
| 87510 | <1% | 339 | $3K | |
| 86593 | <1% | 1,015 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,834 | $3K |
| 97605 | <1% | 60 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,550 | $2K |
| 29125 | <1% | 300 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 957 | $2K |
| 80177 | <1% | 591 | $2K | |
| 64615 | <1% | 45 | $2K | |
| 83540 | <1% | 1,038 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,294 | $2K |
| 72072 | <1% | 44 | $2K | |
| 82550 | <1% | 1,465 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 786 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,206 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,349 | $2K |
| 80076 | <1% | 965 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,781 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,141 | $2K |
| 87088 | <1% | 1,716 | $2K | |
| 82248 | <1% | 365 | $2K | |
| 81002 | <1% | 4,948 | $2K | |
| 77280 | <1% | 13 | $2K | |
| 73523 | <1% | 28 | $2K | |
| 92611 | <1% | 13 | $2K | |
| 94727 | <1% | 41 | $2K | |
| 95819 | <1% | 12 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,272 | $2K |
| 88307 | <1% | 12 | $1K | |
| 74230 | <1% | 26 | $1K | |
| 85014 | <1% | 4,418 | $1K | |
| 71101 | <1% | 126 | $1K | |
| 10060 | <1% | 45 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,123 | $1K |
| 0004A | <1% | 47 | $1K | |
| 85652 | <1% | 1,571 | $1K | |
| 82803 | <1% | 317 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 203 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,212 | $1K |
| 84550 | <1% | 684 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,132 | $1K |
| 73552 | <1% | 77 | $1K | |
| 84436 | <1% | 572 | $1K | |
| 82043 | <1% | 549 | $1K | |
| 87077 | <1% | 707 | $995.54 | |
| 80074 | <1% | 108 | $966.32 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 555 | $948.10 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 891 | $931.51 |
| 64484 | <1% | 13 | $930.27 | |
| 73060 | <1% | 82 | $897.92 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,188 | $895.61 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 794 | $886.86 |
| 72040 | <1% | 64 | $837.31 | |
| 87075 | <1% | 246 | $823.50 | |
| 82247 | <1% | 150 | $776.00 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 93 | $702.37 |
| 82570 | <1% | 420 | $668.02 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 836 | $655.86 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,310 | $618.14 |
| 74022 | <1% | 48 | $555.16 | |
| 77002 | <1% | 16 | $544.52 | |
| 29505 | <1% | 30 | $540.62 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 88 | $525.91 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 479 | $512.97 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 499 | $491.68 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,322 | $478.23 |
| 87205 | <1% | 483 | $474.59 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 778 | $468.12 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 373 | $445.78 |
| 86308 | <1% | 572 | $432.09 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 872 | $426.92 |
| OP637 | <1% | 2,646 | $346.92 | |
| 95874 | <1% | 169 | $322.19 | |
| 86762 | <1% | 42 | $321.04 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 137 | $315.48 |
| 12002 | <1% | 59 | $289.15 | |
| 86618 | <1% | 34 | $284.58 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 536 | $276.51 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 315 | $273.46 |
| 82784 | <1% | 18 | $270.07 | |
| 80164 | <1% | 91 | $267.99 | |
| 29130 | <1% | 62 | $260.30 | |
| 86038 | <1% | 65 | $240.34 | |
| 87081 | <1% | 60 | $233.96 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 330 | $223.06 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,492 | $203.47 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 803 | $193.71 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 143 | $192.99 |
| 82010 | <1% | 61 | $173.61 | |
| 86706 | <1% | 24 | $151.41 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 12 | $141.56 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 276 | $125.23 |
| 86923 | <1% | 13 | $110.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 30 | $104.61 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 36 | $103.92 |
| 84134 | <1% | 34 | $96.73 | |
| 97165 | <1% | 14 | $94.73 | |
| 85018 | <1% | 103 | $88.00 | |
| 84481 | <1% | 15 | $82.50 | |
| 83615 | <1% | 36 | $82.11 | |
| 73100 | <1% | 14 | $70.36 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 139 | $66.32 |
| 85045 | <1% | 15 | $59.34 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 95 | $58.99 |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 51 | $56.48 |
| 88311 | <1% | 14 | $52.34 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 104 | $51.47 |
| 84132 | <1% | 35 | $48.77 | |
| 64644 | <1% | 18 | $43.27 | |
| 82805 | <1% | 13 | $30.45 | |
| 64643 | <1% | 26 | $26.77 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 68 | $25.46 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 82 | $25.23 |
| 82150 | <1% | 27 | $23.81 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 75 | $22.76 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 371 | $20.08 |
| 84156 | <1% | 20 | $19.66 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 31 | $19.37 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 66 | $18.67 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 550 | $12.22 |
| 91300 | 0% | 57 | $0.00 | |
| 91307 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPIPAS, FRANK (EXECUTIVE VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| HMH Hospitals Corporation | Edison, NJ | $6.10M |
| HMH Hospitals Corporation | Edison, NJ | $650K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.